These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

86 related articles for article (PubMed ID: 21185531)

  • 1. HIV-infected adolescents: relationship between atazanavir plasma levels and bilirubin concentrations.
    Nso Roca AP; Larru B; Bellón JM; Mellado MJ; Ramos JT; González MI; Navarro ML; Muñoz-Fernández MÁ; José MI
    J Adolesc Health; 2011 Jan; 48(1):100-2. PubMed ID: 21185531
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Monitoring atazanavir concentrations with boosted or unboosted regimens in HIV-infected patients in routine clinical practice.
    Moltó J; Santos JR; Valle M; Miranda C; Miranda J; Blanco A; Negredo E; Clotet B
    Ther Drug Monit; 2007 Oct; 29(5):648-51. PubMed ID: 17898658
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mid-dosing interval concentration of atazanavir and virological outcome in patients treated for HIV-1 infection.
    Fabbiani M; Di Giambenedetto S; Ragazzoni E; Colafigli M; Prosperi M; Cauda R; Navarra P; De Luca A
    HIV Med; 2010 May; 11(5):326-33. PubMed ID: 20070407
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Exposure-related effects of atazanavir on the pharmacokinetics of raltegravir in HIV-1-infected patients.
    Cattaneo D; Ripamonti D; Baldelli S; Cozzi V; Conti F; Clementi E
    Ther Drug Monit; 2010 Dec; 32(6):782-6. PubMed ID: 20926993
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Atazanavir trough plasma concentration monitoring in a cohort of HIV-1-positive individuals receiving highly active antiretroviral therapy.
    Winston A; Bloch M; Carr A; Amin J; Mallon PW; Ray J; Marriott D; Cooper DA; Emery S
    J Antimicrob Chemother; 2005 Aug; 56(2):380-7. PubMed ID: 15996972
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Within-patient atazanavir trough concentration monitoring in HIV-1-infected patients.
    Crutchley RD; Ma Q; Sulaiman A; Hochreitter J; Morse GD
    J Pharm Pract; 2011 Apr; 24(2):216-22. PubMed ID: 21712217
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Change to a once-daily combination including boosted atazanavir in HIV-1-infected children.
    Macassa E; Delaugerre C; Teglas JP; Jullien V; Tréluyer JM; Veber F; Rouzioux C; Blanche S
    Pediatr Infect Dis J; 2006 Sep; 25(9):809-14. PubMed ID: 16940839
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genetic factors influencing atazanavir plasma concentrations and the risk of severe hyperbilirubinemia.
    Rodríguez-Nóvoa S; Martín-Carbonero L; Barreiro P; González-Pardo G; Jiménez-Nácher I; González-Lahoz J; Soriano V
    AIDS; 2007 Jan; 21(1):41-6. PubMed ID: 17148966
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Therapeutic monitoring and variability of atazanavir in HIV-infected patients, with and without HCV coinfection, receiving boosted or unboosted regimens.
    Regazzi M; Villani P; Gulminetti R; Cusato M; Brandolini M; Tinelli C; Barassi A; Maserati R; Sighinolfi L; D'Arminio Monforte A; Melzi D'Eril GV
    Ther Drug Monit; 2011 Jun; 33(3):303-8. PubMed ID: 21544015
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Atazanavir in pregnancy: impact on neonatal hyperbilirubinemia.
    Mandelbrot L; Mazy F; Floch-Tudal C; Meier F; Azria E; Crenn-Hebert C; Treluyer JM; Herinomenzanahary E; Ferreira C; Peytavin G
    Eur J Obstet Gynecol Reprod Biol; 2011 Jul; 157(1):18-21. PubMed ID: 21492993
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Factors predictive of virological failure on atazanavir in 310 HIV-infected patients.
    Lescure FX; Poirier JM; Meynard JL; Guiard-Schmid JB; Zouai O; Bonnard P; Slama L; Amiel C; Girard PM; Pialoux G
    AIDS; 2010 Jun; 24(10):1593-5. PubMed ID: 20539093
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Coadministration of atazanavir-ritonavir and zinc sulfate: impact on hyperbilirubinemia and pharmacokinetics.
    Moyle G; Else L; Jackson A; Back D; Yapa MH; Seymour N; Ringner-Nackter L; Karolia Z; Gazzard B; Boffito M
    Antimicrob Agents Chemother; 2013 Aug; 57(8):3640-4. PubMed ID: 23689708
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Plasma levels of atazanavir and the risk of hyperbilirubinemia are predicted by the 3435C-->T polymorphism at the multidrug resistance gene 1.
    Rodríguez Nóvoa S; Barreiro P; Rendón A; Barrios A; Corral A; Jiménez-Nacher I; González-Lahoz J; Soriano V
    Clin Infect Dis; 2006 Jan; 42(2):291-5. PubMed ID: 16355344
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Atazanavir plasma concentrations vary significantly between patients and correlate with increased serum bilirubin concentrations.
    Smith DE; Jeganathan S; Ray J
    HIV Clin Trials; 2006; 7(1):34-8. PubMed ID: 16632461
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Penetration of atazanavir in seminal plasma of men infected with human immunodeficiency virus type 1.
    van Leeuwen E; Ter Heine R; van der Veen F; Repping S; Beijnen JH; Prins JM
    Antimicrob Agents Chemother; 2007 Jan; 51(1):335-7. PubMed ID: 17074793
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of atazanavir Ctrough, atazanavir genotypic inhibitory quotient, and baseline HIV genotype as predictors of a 24-week virological response in highly drug-experienced, HIV-infected patients treated with unboosted atazanavir.
    Gianotti N; Seminari E; Guffanti M; Boeri E; Villani P; Regazzi M; Bigoloni A; Schira G; Tiberi S; Fusetti G; Lazzarin A; Castagna A
    New Microbiol; 2005 Apr; 28(2):119-25. PubMed ID: 16035256
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetic properties and tolerability of bevirimat and atazanavir in healthy volunteers: an open-label, parallel-group study.
    Martin DE; Galbraith H; Schettler J; Ellis C; Doto J
    Clin Ther; 2008 Oct; 30(10):1794-805. PubMed ID: 19014835
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Atazanavir plus low-dose ritonavir in pregnancy: pharmacokinetics and placental transfer.
    Ripamonti D; Cattaneo D; Maggiolo F; Airoldi M; Frigerio L; Bertuletti P; Ruggeri M; Suter F
    AIDS; 2007 Nov; 21(18):2409-15. PubMed ID: 18025877
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Clinical utility of atazanavir].
    Ribera Pascuet E; Curran A
    Enferm Infecc Microbiol Clin; 2008 Dec; 26 Suppl 17():55-67. PubMed ID: 20116619
    [TBL] [Abstract][Full Text] [Related]  

  • 20. External validation of the bilirubin-atazanavir nomogram for assessment of atazanavir plasma exposure in HIV-1-infected patients.
    Rekić D; Röshammar D; Bergstrand M; Tarning J; Calcagno A; D'Avolio A; Ormaasen V; Vigan M; Barrail-Tran A; Ashton M; Gisslén M; Äbelö A
    AAPS J; 2013 Apr; 15(2):308-15. PubMed ID: 23224752
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.